Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KVI 020

Next Previous
Drug Profile

KVI 020

Alternative Names: KVI-020; WYE-160020

Latest Information Update: 17 Dec 2013

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble; Wyeth
  • Developer Pfizer; Procter & Gamble
  • Class Imidazolidines; Phenyl ethers; Small molecules; Sulfonamides
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Supraventricular arrhythmias

Most Recent Events

  • 17 Dec 2013 No development reported - Preclinical for Supraventricular arrhythmias in USA (unspecified route)
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top